ATE106249T1 - Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. - Google Patents

Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.

Info

Publication number
ATE106249T1
ATE106249T1 AT88310372T AT88310372T ATE106249T1 AT E106249 T1 ATE106249 T1 AT E106249T1 AT 88310372 T AT88310372 T AT 88310372T AT 88310372 T AT88310372 T AT 88310372T AT E106249 T1 ATE106249 T1 AT E106249T1
Authority
AT
Austria
Prior art keywords
immunogenic potential
immunoglobulin
improved pharmacokinetics
modified immunoglobulins
reduced immunogenic
Prior art date
Application number
AT88310372T
Other languages
English (en)
Inventor
Roberto Cesare Fagnani
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Application granted granted Critical
Publication of ATE106249T1 publication Critical patent/ATE106249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88310372T 1987-11-05 1988-11-03 Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. ATE106249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11815087A 1987-11-05 1987-11-05

Publications (1)

Publication Number Publication Date
ATE106249T1 true ATE106249T1 (de) 1994-06-15

Family

ID=22376776

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88310372T ATE106249T1 (de) 1987-11-05 1988-11-03 Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.

Country Status (5)

Country Link
EP (1) EP0315456B1 (de)
JP (1) JPH01163133A (de)
AT (1) ATE106249T1 (de)
AU (1) AU610946B2 (de)
DE (1) DE3889853D1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6245879B1 (en) * 1999-01-29 2001-06-12 Shell Oil Company Purification of 1,3-propanediol in carbonyl-containing stream
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
ITMI20010347A1 (it) 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP2006508056A (ja) 2002-08-28 2006-03-09 イミュネックス・コーポレーション 心臓血管疾患を治療するための組成物および方法
EP2133362B1 (de) 2003-07-25 2012-04-18 Amgen, Inc Verfahren bezüglich LDCAM und CRTAM
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US7851438B2 (en) 2006-05-19 2010-12-14 GlycoFi, Incorporated Erythropoietin compositions
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US20080096900A1 (en) 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
CA2659820A1 (en) 2006-08-04 2008-02-14 Novartis Ag Ephb3-specific antibody and uses thereof
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
EP2162540A2 (de) 2007-05-22 2010-03-17 Amgen Inc. Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine
HRP20140315T1 (hr) 2007-07-26 2014-05-09 Amgen Inc. Modificirani enzimi lecitin-kolesterol aciltransferaze
EP2235058A2 (de) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid-antikörper und ihre verwendung
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
EP2307456B1 (de) 2008-06-27 2014-10-15 Amgen Inc. Die inhibierung von ang-2 zur behandlung multipler sklerose
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
DK2349341T3 (da) 2008-10-15 2014-01-06 Baxter Int Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129503A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
MX2011013903A (es) 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
WO2010148413A2 (en) 2009-06-19 2010-12-23 Medimmune, Llc Protease variants
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2480888B1 (de) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening-verfahren
US20120231006A1 (en) 2009-11-20 2012-09-13 Amgen Inc. Anti-orai1 antigen binding proteins and uses thereof
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
WO2014152006A2 (en) 2013-03-15 2014-09-25 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
EP3057605A1 (de) 2013-10-18 2016-08-24 Novartis AG Verfahren zur behandlung von diabetes und verwandten erkrankungen
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US20180280474A1 (en) 2015-10-01 2018-10-04 Amgen Inc. Treatment of bile acid disorders
US20180126000A1 (en) 2016-06-02 2018-05-10 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
BR112020010694A2 (pt) 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
CN114096559B (zh) 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate

Also Published As

Publication number Publication date
DE3889853D1 (de) 1994-07-07
EP0315456A2 (de) 1989-05-10
JPH01163133A (ja) 1989-06-27
EP0315456B1 (de) 1994-06-01
AU610946B2 (en) 1991-05-30
EP0315456A3 (en) 1990-03-28
AU2475588A (en) 1989-05-18

Similar Documents

Publication Publication Date Title
ATE106249T1 (de) Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
Davis et al. A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking
EP0527821A4 (en) Oxidation resistant thrombomodulin analogs
SE8501022D0 (sv) Format alster och forfarande for dess framstellning
ATE108799T1 (de) Konjugate von in position c-3 eine detergens- kette enthaltenden vinca-derivaten.
DE69333107T2 (de) Dualer träger für immunogene konstrukte
FI102289B1 (fi) Pinnoitekoostumus
FI903464A0 (fi) Foerfarande foer oxiderande denaturering av proteinanalyter.
DE59008404D1 (de) Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oder IgA-haltige Immunglobulinpräparate.
ATE259878T1 (de) Verfahren zur verbesserung der immunogenität einer immunogenen zusammensetzung oder eines haptens und verwendung zur herstellung von impfstoffen
DE68906011D1 (de) Chitosan enthaltendes kosmetisches praeparat.
FR2522967B1 (fr) Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
ATE183241T1 (de) Impstoff gegen streptococcus suis-infektion
ATE16603T1 (de) Immunoglobulinkonjugate.
SE7608174L (sv) Forfarande for framstellning av antiserum
KR860003825A (ko) 안정한 현탁액 제조용 고체 약물제형의 제조방법
FI854511A0 (fi) Vattenloesliga polymerer.
DK0529019T3 (da) Nematodevaccine
SE8602523L (sv) 2-alkyl- eller -aralkyltio-1-cykloalken-1-karboxamider och deras sulfoxider, sett for deras framstellning och deras anvendning for syntes av tri- och 4,5-tetrametylen-4-isotiazolin-3-oner
PT91571A (pt) Verfahren fuer die herstellung von phyto und zoosterole und deren derivate mit verbesserter wasseroeslichkeit
DE3884315D1 (de) Verwendung von Epithioderivaten ungesättigter Kohlenstoffverbindungen als Weichmacher sowie diese enthaltende Dichtungsmassen.
SE8504228L (sv) Tumordodande emne
DE69128095D1 (de) Azelluläre impfstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties